Vantage Consulting Group’s Core Laboratories CLB Stock Holding History

Vantage Consulting Group’s Portfolio CLB Stock Details CLB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-301	Closed	-$8K	–	387
2020 Q4	$8K	Buy	+301	New	+$6.15K	﹤0.01%	1309

Other funds holding CLB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

AKO Capital London, United Kingdom $5.11B AUM 2.56% 1-Year Est. Return

VanEck Associates New York $133B AUM 72.99% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vantage Consulting Group's CLB Position: Q1 2021 in Review

Vantage Consulting Group sold out of Core Laboratories (CLB) in Q1 2021, closing a stake of 301 shares — an estimated $8K sold.

Vantage Consulting Group first reported a position in CLB in Q4 2020 and held it in 1 quarter. The position peaked at $8K in Q4 2020. 183 funds tracked by Wall St. Rank hold CLB as of Q1 2021.

Vantage Consulting Group reported no remaining Core Laboratories position as of Q1 2021 after selling out during the quarter.
Vantage Consulting Group sold 301 Core Laboratories shares in Q1 2021, an estimated $8K.
Vantage Consulting Group first reported a position in Core Laboratories in Q4 2020 and held it in 1 quarter.
Vantage Consulting Group's Core Laboratories position peaked at $8K in Q4 2020.
183 funds tracked by Wall St. Rank held Core Laboratories as of Q1 2021.

Based on Vantage Consulting Group's 13F filing for Q1 2021, filed 14 May 2021.